Abstract Number: 938 • 2016 ACR/ARHP Annual Meeting
Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Background/Purpose: Sacroiliitis, as detected by plain radiographs of the sacroiliac joints (SIJ), has been reported in a third of the psoriatic arthritis (PsA) population. (1)…Abstract Number: 939 • 2016 ACR/ARHP Annual Meeting
Circulating IgG4 Antibody Secreting Cells Are Better Biomarker of Disease Activity Compared to Serum IgG4 Levels in Patients with IgG4-Related Disease
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition with a consistent set of pathological features that affect multiple organ systems. Patients with IgG4-RD typically present…Abstract Number: 940 • 2016 ACR/ARHP Annual Meeting
A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can lead to irreversible damage. No approved therapies for IgG4-RD exist. We…Abstract Number: 941 • 2016 ACR/ARHP Annual Meeting
An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can affect nearly any organ and lead to irreversible damage. To evaluate…Abstract Number: 942 • 2016 ACR/ARHP Annual Meeting
A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease and colchicine is the mainstay of treatment. Around 30-45% of FMF patients were reported…Abstract Number: 943 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever Who Underwent Kidney Transplantation
Background/Purpose: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by self-limiting febrile attacks associated with serosal or synovial inflammation as well as increased…Abstract Number: 944 • 2016 ACR/ARHP Annual Meeting
A New Syndrome in the Spectrum of Cryopyrin-Associated Periodic Syndromes (CAPS) Caused By the Novel R918Q NLRP3 Mutation
Background/Purpose: Mutations in NLRP3 cause 3 different dominantly inherited autoinflammatory syndromes: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID).…Abstract Number: 945 • 2016 ACR/ARHP Annual Meeting
When and Where Musculoskeletal Ultrasound Might Replace Magnetic Resonance in the Assessment of Patients with Juvenile Idiopathic Arthritis?
Background/Purpose: Magnetic resonance imaging (MRI) is the most attractive imaging modality for the investigation of patients with juvenile arthritis (JIA). Musculoskeletal ultrasound (MSUS) has intuitive…Abstract Number: 946 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Second-Line Treatment Strategies for Lyme Arthritis in Children
Background/Purpose: First-line treatment for Lyme arthritis is fairly standardized, but second-line strategies are more variable. We compared the effectiveness of oral antibiotics, intra-articular glucocorticoid injections (IAGC),…Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…Abstract Number: 950 • 2016 ACR/ARHP Annual Meeting
Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Background/Purpose: Information regarding the history of patients with JIA after systemic treatment withdrawal would be helpful in driving the choice of duration therapy. While some…Abstract Number: 951 • 2016 ACR/ARHP Annual Meeting
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Background/Purpose: According to national guidelines issued in May 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish…Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
ACR Meeting Abstracts